Inscrição YC de Kernal Biologics
Kernal Biologics passou pela Y Combinator no batch Summer 2020 como uma empresa Healthcare. Abaixo: o que a empresa faz, quem a fundou e sua inscrição para a YC, reconstruída pergunta por pergunta no formulário real da YC.
- Batch YC
- Summer 2020
- Indústria
- HealthcareTherapeutics
- Tamanho da equipe
- 20
- Status
- Active
- Lançada
- 2020
Fundadores
Yusuf ErkulFounder
Jeff OzdemirFounder
Burak YILMAZFounder
O que Kernal Biologics faz
Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week. Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA. With roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. Sr. VP of R&D Manfred Kraus is a leader in immuno-oncology, who was most recently Scientific Sr. Director at Bristol-Myers Squibb (BMS).
Inscrição YC de Kernal Biologics, reconstruída
Inscrição Y Combinator
Kernal Biologics, lote Summer 2020. As verdadeiras perguntas do formulário, respondidas com dados públicos.
- Founders2
- Company7
- Progress7
- Idea4
- Equity3
- Curious2
- Batch Preference1
Company
Kernal Biologics
mRNA 2.0 therapies targeting specific cells
We're building selective mRNA-LNP immunotherapies that deliver mRNA precisely to specific immune cells. Our lead program, KR-402, targets T cells to program CAR-T therapies directly in the body and can deplete B cells within a week. This lets us treat cancer and autoimmune diseases with fewer off-target effects than current mRNA approaches.
We live in Cambridge, MA, and Kernal is based there. After YC, we'd remain in Cambridge because that's where our team, science, and investors are concentrated.
Cambridge is a biotech hub with access to top academic talent and proximity to investors, which is critical for developing complex mRNA therapeutics. Being near MIT and Harvard also helps us recruit and collaborate on cutting-edge science.
21 respostas a mais na inscrição completa
Founders, Progress, Idea, Equity, Curious, Batch Preference estão na versão completa. Crie uma conta gratuita para abri-la no YC Insights, ao lado de todos os outros batches da YC.
Perguntas Frequentes
Esta é a inscrição real da YC de Kernal Biologics?
Não. A Y Combinator mantém as inscrições submetidas em privado. Esta é uma reconstrução: as perguntas reais do formulário da YC, respondidas a partir dos dados públicos de Kernal Biologics (notas de lançamento, históricos de fundadores, descrição do produto). Mostra como uma empresa como Kernal Biologics se apresentaria à YC, não o texto que eles submeteram.
Em qual batch da YC Kernal Biologics esteve?
Kernal Biologics fez parte do batch Summer 2020 da Y Combinator.
Quem fundou o Kernal Biologics?
O Kernal Biologics foi fundado por Yusuf Erkul, Jeff Ozdemir, Burak YILMAZ.
O que o Kernal Biologics faz?
Kernal is creating mRNA 2.0 therapies that work in specific cells
Como eu leio o application completo reconstruído?
Crie uma conta gratuita no Round Funded. A versão completa de 26 respostas do application do Kernal Biologics, e de todos os outros lotes do YC, está no YC Insights.
Mais startups YC como Kernal Biologics
